FDA Clears Secukinumab for Use in Polymyalgia Rheumatica
The FDA approved Novartis' secukinumab (Cosentyx) for treating polymyalgia rheumatica (PMR) in adults unresponsive to corticosteroids. The approval follows positive phase 3 REPLENISH trial results, showing sustained remission rates of 41.2% and 40.6% for 300 mg and 150 mg doses, respectively, compared to 20.4% for placebo. Secukinumab is already approved for several other inflammatory conditions.
How this was made
The 30-second read
Why it matters
The approval is supported by Phase 3 REPLENISH results showing nearly doubled sustained remission rates versus placebo and no new safety signals, positioning secukinumab as a steroid-sparing option in PMR.
Market read
Traders can treat this as a fresh regulatory catalyst for Novartis’ Cosentyx franchise, with potential incremental demand from a new PMR label and a near-term sentiment tailwind.
What to watch
Real-world uptake will depend on payer coverage, clinician comfort with IL-17 in PMR, and how quickly EU approval and guideline updates translate into prescribing behavior.
Background
Secukinumab (Cosentyx) is an anti-IL-17A monoclonal antibody already approved for multiple inflammatory diseases; this FDA decision adds PMR for adults with inadequate response to corticosteroids or inability to taper.
Ticker impact
FDA approval of Novartis' secukinumab (Cosentyx) for polymyalgia rheumatica expands the drug’s labeled indications beyond existing autoimmune uses.
Likely positive bias as investors price in expanded addressable market and potential uptake from steroid-inadequate or intolerant PMR patients.
The article is a direct FDA regulatory approval tied to Novartis’ product, with supportive Phase 3 REPLENISH efficacy and no new safety signals reported.
Market effects
Reinforces IL-17 pathway competitiveness in inflammatory rheumatology and may shift treatment expectations toward steroid-sparing biologics.
US label expansion is immediate; EU marketing authorization is expected soon, potentially extending the catalyst window.
Could accelerate global adoption discussions for PMR management guidelines where biologics are considered after steroid failure or intolerance.
Counterpoint
PMR is a niche indication relative to Cosentyx’s broader psoriasis/psoriatic arthritis footprint, so near-term financial impact may be modest versus market expectations.
Key entities
- companyNovartis
Manufacturer of secukinumab (Cosentyx), whose product received FDA approval for polymyalgia rheumatica.
- drugsecukinumab (Cosentyx)
Anti-IL-17A monoclonal antibody approved for PMR in adults with inadequate steroid response or steroid intolerance.
- clinical_trialREPLENISH trial
Phase 3 program evaluating secukinumab plus a prednisone taper in adults with PMR.
- regulatorEuropean Commission
Expected to issue a final EU decision soon after EMA’s positive recommendation.




